Sabrina Katzdobler, Georg Nübling, Martin Klietz, Urban M Fietzek, Carla Palleis, Alexander M Bernhardt, Florian Wegner, Meret Huber, Sophia Rogozinski, Luisa-Sophie Schneider, Eike Jakob Spruth, Aline Beyle, Ina R Vogt, Moritz Brandt, Niels Hansen, Wenzel Glanz, Kathrin Brockmann, Annika Spottke, Daniel C Hoffmann, Oliver Peters, Josef Priller, Jens Wiltfang, Emrah Düzel, Anja Schneider, Björn Falkenburger, Thomas Klockgether, Thomas Gasser, Brigitte Nuscher, Christian Haass, Günter Höglinger, Johannes Levin
BACKGROUND: Multiple system atrophy (MSA), an atypical parkinsonian syndrome, is a rapidly progressive neurodegenerative disease with currently no established fluid biomarkers available. MSA is characterized by an oligodendroglial α-synucleinopathy, progressive neuronal cell loss and concomitant astrocytosis. Here, we investigate glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as fluid biomarkers for differential diagnosis, assessment of clinical disease severity and prediction of disease progression in MSA...
September 10, 2024: Journal of Neurology